Avoiding N-nitrosodimethylamine formation in metformin pharmaceuticals by limiting dimethylamine and nitrite
Joerg Schlingemann(Merck KGaA, Darmstadt (Germany)), Sandra Masanes(Merck KGaA, Darmstadt (Germany)), Fanny Schooren(Merck KGaA, Darmstadt (Germany)), Judith Keitel(Merck KGaA, Darmstadt (Germany)), Anja Goettsche(Merck KGaA, Darmstadt (Germany)), Maic Seegel(Merck KGaA, Darmstadt (Germany)), Philipp Reifenberg(Merck KGaA, Darmstadt (Germany)), Phillip Krueger(Merck KGaA, Darmstadt (Germany)), Tobias Schuster(Merck KGaA, Darmstadt (Germany)), Stefan Leicht(Merck KGaA, Darmstadt (Germany)), Tim Müller(Merck KGaA, Darmstadt (Germany)), Stephanie L. Wetzel(Merck KGaA, Darmstadt (Germany)), Laura Bourasseau(Merck KGaA, Darmstadt (Germany)), Brunhilde Guessregen(Merck KGaA, Darmstadt (Germany)), Céline Boucley(Merck KGaA, Darmstadt (Germany)), M. Walker(AstraZeneca (United Kingdom)), Thibaut Chemarin(Merck KGaA, Darmstadt (Germany)), Celine Pegues(Merck KGaA, Darmstadt (Germany)), Mike Liebhold(Merck KGaA, Darmstadt (Germany)), Sebastian Hickert(Merck KGaA, Darmstadt (Germany)), Christoph Saal(Boehringer Ingelheim (Germany)), Annette Kirsch(Merck KGaA, Darmstadt (Germany)), Bruno Mouton(Merck KGaA, Darmstadt (Germany)), Matthias Fritzsche(Merck KGaA, Darmstadt (Germany)), Caroline Celdran(Merck KGaA, Darmstadt (Germany))
Cited by 68
Related Papers
The Nitrosamine “Saga”: Lessons Learned from Five Years of Scrutiny
|Organic Process Research & Development|2023|82
NDMA analytics in metformin products: Comparison of methods and pitfalls
|European Journal of Pharmaceutical Sciences|2021|47
Control of N-nitrosamine impurities in drug products: Progressing the current CPCA framework and supporting the derivation of robust compound specific acceptable intakes
|Regulatory Toxicology and Pharmacology|2024|13